Our study assessed the impact of using Control-IQ technology, an automated insulin delivery system, on achievement of a Healthcare Effectiveness Data and Information Set (HEDIS) quality measure ...

– Enhanced features extend automated insulin delivery (AID) to people ages 2 years and older with type 1 diabetes and adults with type 2 diabetes – Control-IQ+ automated insulin delivery technology ...

Tandem Diabetes Care, Inc. TNDM recently commercially launched Control-IQ+ technology - the latest generation of its advanced hybrid closed-loop algorithm in the United States. Control-IQ+ is ...

Tandem Diabetes (TNDM) announced the United States commercial launch of Control-IQ+ technology, the latest generation of the company’s advanced hybrid closed-loop algorithm. Control-IQ+, compatible ...

CEO John Sheridan highlighted that Tandem achieved over 20% growth for the third consecutive quarter, with record sales both in the U.S. and internationally. The company's operational focus on ...

Tandem Diabetes Care Inc.’s Control-IQ+ automated insulin delivery system improved multiple measures of glycemic control in individuals with type 2 diabetes who use insulin, a study presented March 19 ...

Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, today announced Health Canada authorization for distribution of the Tandem t:slim mobile ...